Key result
Proteomic and phosphoproteomic profiling identifies two advanced HF subgroups with divergent remodeling and survival trajectories.
Why the study?
Molecular heterogeneity in heart failure is a major barrier to effective therapy development, necessitating molecular classification of patients.
Observational (n=149)
Answers are grounded in this paper and cite their sources.
Proteomic and phosphoproteomic profiling of advanced heart failure tissues identifies two distinct molecular subgroups that predict survival trajectories, providing a framework for precision-guided therapies.
Molecular heterogeneity in heart failure (HF) is increasingly recognized as a major barrier to effective therapy development. Here we performed proteomic profiling of left ventricular tissues from 149 patients with advanced HF spanning nine clinical etiologies. Despite clinical diversity, etiology-stratified analyses revealed convergence toward a shared end-stage proteomic landscape. By contrast, unbiased proteome-based clustering stratified patients into two molecular subgroups characterized by divergent remodeling phenotypes, including differences in fibrosis and immune cell infiltration. Phosphoproteomic profiling was consistent with this stratification, and the analyses further uncovered selective activation of druggable signaling networks in a molecularly defined subgroup of patients. Moreover, our remodeling-associated subgrouping proteins also stratified patients and predicted survival trajectories in an independent plasma-based HF cohort from the UK Biobank, extending our findings to earlier disease stages. Together, our study provides a rich resource for molecular classification of patients with HF, supporting the development of precision-guided therapeutic strategies.
No takes yet. Share an insight, caveat, or question.
Hamed et al. (2026) conducted an observational in advanced heart failure (n=149). Proteomic and phosphoproteomic profiling was evaluated on Molecular subgroups and survival trajectories. Proteomic and phosphoproteomic profiling stratified patients with advanced heart failure into two molecular subgroups characterized by divergent remodeling phenotypes and predicted survival trajectories.
Synapse has enriched 10 related papers. Consider them for comparative context: